Molecular Breast Imaging: A Better Way to Spot Tumors in Dense Tissue

Key points
- Molecular breast imaging (MBI), a new screening method for breast cancer, identifies tumors in dense tissue that often aren’t visible with mammography.
- MBI overcomes a shortcoming of mammography, which is taken with X-rays.
- “With MBI, a tumor is easy to see, even if it’s in dense breast tissue,” says Dr.
- Here’s why: With MBI, a woman is given an injection of a short-lived radioactive agent.
Molecular breast imaging (MBI), a new screening method for breast cancer, identifies tumors in dense tissue that often aren’t visible with mammography. In the March issue of Mayo Clinic Women’s HealthSource, Deborah Rhodes, M.D., a Mayo Clinic researcher who helped develop the technology, discusses why MBI may eventually serve as an adjunct to mammography.
MBI overcomes a shortcoming of mammography, which is taken with X-rays. The X-ray imagery doesn’t differentiate between tumors and dense breast tissue. On a mammogram, they both appear white.
“With MBI, a tumor is easy to see, even if it’s in dense breast tissue,” says Dr. Rhodes.
Here’s why: With MBI, a woman is given an injection of a short-lived radioactive agent. This material accumulates in tumor cells more than it does in normal cells. Using a radiation-detecting camera, tumors show up as hot spots on the resulting image.
In a recent Mayo Clinic study comparing MBI with mammography, MBI detected three times as many cancers in women with dense breast tissue and an increased risk of breast cancer. Another advantage over mammography: MBI also demonstrated fewer false positives, meaning the results appear abnormal but are noncancerous.
For now, MBI use is limited to research. The focus is to reduce the dose of radiation needed to perform MBI. The risk from the radiation dose of one or two MBI scans is extremely low. But to safely use MBI annually or every few years, the radiation dose needs to be reduced.
“Our goal is to have a dose that’s no higher than that from a routine mammogram,” says Dr. Rhodes. “If we get results that are similar to, or better than, our last study, we’ll be well on our way to supporting MBI as an option for women with dense breast tissue.”
Mayo Clinic Women’s HealthSource is published monthly to help women enjoy healthier, more productive lives. Revenue from subscriptions is used to support medical research at Mayo Clinic. To subscribe, please call 800-876-8633, extension 9751, or visit www.bookstore.mayoclinic.com.
Source: Mayo Clinic
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsMammography-detected breast cancer in 40-49 year-olds has better prognosis
Based on a study of nearly 2,000 breast cancer patients, researchers at the Swedish Cancer Institute in Seattle say that, in women between the ages of 40 and 49, breast cancers detected by mammography have a better…
23 February 2012
NewsA new molecular mechanism in breast cancer development
About 10% of breast cancers are due to mutations in genes called BRCA1 and BRCA2. However, the molecular mechanism by which alteration of these genes greatly increases the risk of cancer is not fully understood. In a…
17 November 2011
NewsConsider the breast and lungs when determining thoracic imaging protocols
Carefully consider the radiation dose to the breast and lungs before deciding which CT protocol to use for thoracic imaging of individual patients, a new study cautions. The study compared organ doses to the breast,…
3 October 2011



